This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
Annexin Pharmaceuticals is a Swedish privately held biotech company developing new therapeutic approaches for inflammatory cardiovascular diseases. The concept for the therapy is based on the anti-inflammatory properties of Annexin A5, a body own protective protein that acts simultaneously against several key pathogenic mechanisms of cardiovascular diseases. The company is currently focusing on treatment of peripheral artery disease (PAD).
- Martz, Lauren (May 26, 2014). "Annexin: Attenuating vascular inflammation" (PDF). BioCentury: A18. Retrieved 1 February 2015.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|